BMO Capital analyst Connor Murphy has initiated coverage on Trevi Therapeutics with an Outperform rating and announced a price target of $36. This new target suggests a positive outlook for the NASDAQ-listed company, which trades under the ticker symbol TRVI.

Rating and Price Target Details

The initiation marks the start of formal coverage by BMO Capital, providing a valuation benchmark for investors. The Outperform rating indicates expectations for the stock to perform better than the market average.

Trevi Therapeutics, Inc. has announced that its senior management will participate in several upcoming conferences in June and July. The clinical-stage biopharmaceutical company, which is developing the investigational therapy Haduvio for chronic cough, will engage with investors and industry professionals at three key events. The schedule underscores the company's commitment to advancing its pipeline and communicating its progress to stakeholders.

Conference Schedule

Trevi Therapeutics will attend the following events, with specific executives representing the company:

About Trevi Therapeutics

Trevi Therapeutics, Inc. is focused on developing Haduvio (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF-related chronic cough and in patients with RCC. The therapy acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough.

Chronic cough in patients with IPF and non-IPF ILD represents a high unmet need with no FDA-approved therapies. There are approximately 140,000 U.S. patients with IPF, two-thirds of whom experience uncontrolled chronic cough. Additionally, there are approximately 228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. RCC affects approximately 2-3 million U.S. patients and is defined as a persistent cough lasting more than 8 weeks despite treatment for an underlying condition. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER, though its safety and efficacy have not been evaluated by any regulatory authority.